Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Libman-Sacks Endocarditis

  • Author: Xiushui (Mike) Ren, MD; Chief Editor: Richard A Lange, MD, MBA  more...
 
Updated: Dec 23, 2014
 

Background

Libman-Sacks endocarditis (otherwise known as verrucous, marantic, or nonbacterial thrombotic endocarditis) is the most characteristic cardiac manifestation of the autoimmune disease systemic lupus erythematosus. Libman and Sacks first published a description of the atypical, sterile, verrucous vegetations of this form of endocarditis in 1924.[1] The condition most commonly involves the mitral and aortic valves, but all 4 cardiac valves and the endocardial surfaces can be involved.[2]

Postmortem studies describe mulberrylike clusters of verrucae on the ventricular surface of the posterior mitral leaflet, often with adherence of the mitral leaflet and chordae to the mural endocardium. The lesions typically consist of accumulations of immune complexes and mononuclear cells. The condition is not always recognized on echocardiographic images. With the introduction of steroid therapy for systemic lupus erythematosus, improved longevity of patients appears to have changed the spectrum of valvular disease.

Valvular abnormalities occur as masses (classic Libman-Sacks vegetations; see the image below), diffuse leaflet thickening, valvular regurgitation, and, infrequently, stenosis. Valvular regurgitation is noted most commonly in patients with leaflet thickening, which is thought to represent the chronic healed phase of disease. The left-sided valves are involved most often.

Transesophageal image of a mitral valve with masse Transesophageal image of a mitral valve with masses characteristic of Libman-Sacks endocarditis.

Lesions similar to those described by Libman and Sacks also occur in association with primary or secondary antiphospholipid syndrome. However, the role of antiphospholipid antibodies in the pathogenesis of Libman-Sacks endocarditis is disputed. Malignancy and hypercoagulable states are also associated with the formation of verrucous endocarditis.

Lesions are usually clinically silent, without significant valvular dysfunction. When such dysfunction does occur, however, it can result in cardiac failure. Embolic phenomena and secondary infective endocarditis, although uncommon, can also complicate valvular abnormalities and can cause neurologic and systemic complications. The risk of systemic emboli is increased substantially in the presence of mitral stenosis, atrial fibrillation, or both.

Valvular regurgitation and, rarely, stenosis may result in heart failure and arrhythmias, such as atrial fibrillation.

Next

Etiology

Antiphospholipid antibodies

The pathogenesis of Libman-Sacks endocarditis is unknown. However, antiphospholipid antibodies are frequently associated with valvular abnormalities. These autoimmune antibodies are directed against negatively charged phospholipids present in endothelial cell membranes.

Although immunohistologic studies suggest a pathogenetic role for antiphospholipid antibodies, a similar prevalence and severity of valvular disease have been described in lupus patients without these antibodies; their presence does not seem to be required.

Impairment of antithrombotic mechanisms

Impaired antithrombotic mechanisms present in patients with antiphospholipid syndrome, malignancy, and hypercoagulable states may play a role in the pathogenesis of thrombosis and valvular lesions. Areas of endothelial damage caused by turbulence and the jet effect on the left side of the heart are potential sites of platelet and fibrin deposition.

Steroid therapy

Steroid therapy is implicated in the modification of the nature of valvular abnormalities and in the dysfunction observed in patients with systemic lupus erythematosus.

With the introduction of steroid therapy, valvular thickening and regurgitation appear to occur more commonly, with histologically active lesions identified less frequently. However, data are circumstantial and may reflect improved longevity of patients. Firm conclusions cannot be made.

Previous
Next

Epidemiology

Valvular abnormalities are commonly detected in patients with lupus. The characteristic Libman-Sacks vegetations are reported postmortem in approximately 50% of fatal lupus cases. Current echocardiographic studies reveal valvular abnormalities in 28-74% of patients, with valvular masses in 4-43% of patients with systemic lupus erythematosus. Higher rates are generally detected with transesophageal imaging and in subjects with antiphospholipid antibodies (41% with masses), although this observation is not universal.

One cohort study reported that Libman-Sacks endocarditis was found in 11% of patients with lupus.[3] Pure mitral regurgitation was the most common valvular abnormality, followed by aortic regurgitation, combined mitral stenosis and regurgitation, and combined aortic stenosis and regurgitation. At baseline, Libman-Sacks endocarditis was significantly associated with underlying lupus disease activity. During the follow-up echocardiograph, patients with previous valvular lesions had worsened valve function, and more patients developed new valvular lesions.

Coexistent leaflet thickening is noted in 71% of patients with valvular masses. Echocardiography detects valvular thickening in 19-52% of patients with systemic lupus erythematosus.

In older patients, who have a longer mean duration of systemic lupus erythematosus and have received a larger cumulative dose of steroids, valves that appear to be thickened and rigid occur more commonly than verrucous vegetations.

The prevalence of regurgitation in patients with thickened valve leaflets has been reported to be as high as 73%.

The prevalence of valvular abnormalities detected during echocardiography in patients with primary antiphospholipid syndrome has been reported at 30-32%. Abnormal echocardiographic findings are most common in individuals with peripheral arterial thromboses, having been noted in up to 64% of patients. Leaflet thickening is the most frequent abnormality, having been noted in 10-24% of patients. Vegetationlike masses occur in 6-10% of patients.

Sex- and race-related demographics

Systemic lupus erythematosus and primary antiphospholipid syndrome occur 5-9 times more often in women; therefore, patients with cardiac valvular lesions are generally young women. In the United States, statistics show systemic lupus erythematosus to be more prevalent in black and Hispanic women.

Previous
Next

Prognosis

Longitudinal data of valvular abnormalities are limited. Two series reported no progression of mild or moderate regurgitation to severe regurgitation over a 2- to 3-year period and reported only isolated cases of mildly progressive stenosis.

Prognosis is probably dependent on the underlying disease activity of systemic lupus erythematosus and associated renal and myocardial dysfunction.

Morbidity and mortality

Mortality is undefined. Patients with systemic lupus erythematosus have an increased mortality rate compared with the general population. Cardiovascular mortality is ranked third in these patients but includes a wide spectrum of pathology.

The combined rate of heart failure, valve replacement, thromboembolism, and secondary infective endocarditis has been reported to be as high as 22% in lupus patients with valvular disease, compared with 8% of patients without valvular disease. Most patients do not have clinically significant valvular dysfunction.

Regurgitation is noted on echocardiographic images in 25-61% of patients with lupus and in 10-24% of patients with primary antiphospholipid syndrome. The prevalence of moderate or severe regurgitation has been reported in 0-12% (severe in 3%, moderate in 9%) of patients with antiphospholipid syndrome and in 4-26% of patients with lupus. The reported need for valve replacement varies from 1-8% of cases.

The likely prevalence of secondary infective endocarditis is low, but it has not been widely reported. Potential contributing factors to infective endocarditis are systemic lupus erythematosus, medications prescribed for lupus, and underlying valvular abnormalities.

The occurrence of clinically significant embolic phenomena is thought to be low. Although stroke rates are higher in patients with lupus and antiphospholipid syndrome, multifactorial etiologies for neurologic events are often present, making the specific contribution of valvular abnormalities difficult to determine.

A study by Roldan et al, however, indicated that in patients with systemic lupus erythematosus, Libman-Sacks endocarditis increases the risk for embolic cerebrovascular disease. The 6-year study involved 30 patients with acute neuropsychiatric systemic lupus erythematosus (NPSLE), 46 patients with systemic lupus erythematosus but without NPSLE, and 26 healthy controls, with members of the study followed up for a median period of 52 months.[4]

The results of the study indicated that Libman-Sacks vegetations are an independent risk factor for NPSLE, neurocognitive dysfunction, and brain lesions, either separately or in a combination of all three. According to the report, the number of cerebromicroemboli per hour was three-fold greater in patients with vegetations, while cerebral blood flow was lower and the incidence of neurocognitive dysfunction, cerebral infarcts, and strokes/transient ischemic attacks and overall NPSLE events was higher. Brain lesion load was also greater.[4]

Previous
Next

Patient Education

Give patients on anticoagulation written information regarding potential drug interactions, dietary advice, the need for regular monitoring of the international normalized ratio, and the warning symptoms of hemorrhage. Referral to an anticoagulation clinic may be appropriate.

Educate patients about the need for antibiotic prophylaxis in case of lacerations or in instances of dental work or other procedures.

Information regarding systemic lupus erythematosus is available through the following Web sites:

For patient education information, see Lupus (Systemic Lupus Erythematosus).

Previous
 
 
Contributor Information and Disclosures
Author

Xiushui (Mike) Ren, MD Cardiologist, The Permanente Medical Group; Associate Director of Research, Cardiovascular Diseases Fellowship, California Pacific Medical Center

Xiushui (Mike) Ren, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Society of Echocardiography

Disclosure: Nothing to disclose.

Coauthor(s)

Elizabeth W Ryan, MBBS Visiting Medical Officer, Department of Medicine, Division of Cardiology, Barwon Health, Australia

Elizabeth W Ryan, MBBS is a member of the following medical societies: Cardiac Society of Australia and New Zealand, Royal Australasian College of Physicians

Disclosure: Nothing to disclose.

Elyse Foster, MD Director of Non-Invasive Cardiology, Department of Medicine, Division of Cardiology, Professor of Medicine, University of California, San Francisco, School of Medicine

Elyse Foster, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Heart Association, American Society of Echocardiography

Disclosure: Received grant/research funds from Abbott Vascular Structural Heart for research.

Chief Editor

Richard A Lange, MD, MBA President, Texas Tech University Health Sciences Center, Dean, Paul L Foster School of Medicine

Richard A Lange, MD, MBA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, Association of Subspecialty Professors

Disclosure: Nothing to disclose.

Acknowledgements

Craig T Basson, MD, PhD Gladys and Roland Harriman Professor of Medicine, Director of the Center for Molecular Cardiology, Director of Cardiovascular Research, Division of Cardiology, Department of Medicine, Weill Cornell Medical College; Attending Physician, New York Presbyterian Hospital

Craig T Basson, MD, PhD is a member of the following medical societies: American College of Cardiology and American Heart Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med. 1924. 33:701-37.

  2. Moaref AR, Afifi S, Rezaian S, Rezaian GR. Isolated tricuspid valve Libman-Sacks endocarditis and valvular stenosis: unusual manifestations of systemic lupus erythematosus. J Am Soc Echocardiogr. 2010 Mar. 23(3):341.e3-5. [Medline].

  3. Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. July 2007. 120:636-42. [Medline]. [Full Text].

  4. Roldan CA, Sibbitt WL Jr, Qualls CR, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013 Sep. 6(9):973-83. [Medline]. [Full Text].

  5. Nighoghossian N, Trouillas P, Perinetti M, Barthelet M, Ninet J, Loire R. [Lambl's excrescence: an uncommon cause of cerebral embolism]. Rev Neurol (Paris). 1995 Oct. 151(10):583-5. [Medline].

  6. Roldan CA, Qualls CR, Sopko KS, Sibbitt WL Jr. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rheumatol. February 2008. 35:224-9. [Medline]. [Full Text].

  7. Plastiras SC, Pamboucas CA, Tektonidou M, Toumanidis ST. Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. Eur J Echocardiogr. 2010 Mar. 11(2):184-5. [Medline].

  8. [Guideline] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15. 62(16):e147-239. [Medline].

  9. Dandekar UP, Watkin R, Chandra N, Santo KC, Bhudia S, Pitt M, et al. Aortic valve replacement for Libman-Sacks endocarditis. Ann Thorac Surg. 2009 Aug. 88(2):669-71. [Medline].

  10. Bouma W, Klinkenberg TJ, van der Horst IC, Wijdh-den Hamer IJ, Erasmus ME, Bijl M, et al. Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg. 2010 Mar 23. 5(1):13. [Medline]. [Full Text].

 
Previous
Next
 
Transesophageal image of a mitral valve with masses characteristic of Libman-Sacks endocarditis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.